Search PubMed⌕ Search

Biomedical subjects

A Tada

Publications and source records attributed to A Tada.

At least 109 records · Page 6Linked to original sources
PubMed1984

Two-step mechanism of myofibrillar protein degradation in acute plasmocid-induced muscle necrosis.

Acute muscle necrosis was induced in rats by intramuscular injection of plasmocid, a known myotoxic agent. A single injection of 5 mg/ml plasmocid produced massive fiber necrosis with extensive phagocytosis. Plasmocid administration led to a preferential decrease of alpha-actinin with preservation of other structural proteins within 3 h after injection, and large increases (2-7-fold) in the activities of acid hydrolases, cathepsins B and L, cathepsin D and alpha-galactosidase within 48 h after injection. The plasmocid-induced stimulation of alpha-actinin loss seen at 3 h, when no increases of acid hydrolases occurred, could be inhibited by a cysteine protease inhibitor, Ep-475 (E-64-c), and EGTA. On the other hand, increased lysosomal enzyme activity seemed to have a close correlation with the appearance of invading mononuclear cells, probably macrophages, and not muscle lysosomes. These observations suggest that a two step mechanism of protein degradation (nonlysosomal and lysosomal processes) possibly occurs in plasmocid-induced muscle degradation and macrophages can serve as a main endogenous reservoir of proteases in pathological states.

Actinin↗
PubMed1984

[A combination chemotherapy consisting of vincristine, etoposide and cyclophosphamide (VEC) for small cell carcinoma of the lung].

Twenty-nine patients with small cell carcinoma of the lung were treated with a combination therapy consisting of vincristine 1 mg/m2 i.v. day 1, etoposide 200 mg/body p.o day 1-5 and cyclophosphamide 500 mg/m2 i.v. day 1 (VEC) in 3 week interval. After 2 courses of VEC, four out of 10 patients with limited disease (LD) showed a complete response (CR), while 7 out of 19 patients with extensive disease (ED) obtained a CR. Six patients with LD and 6 patients with ED received subsequent radiotherapy to primary tumors and to regional lymph nodes, and 5 with LD and 3 with ED attained a CR. Overall complete response was observed in 9 patients (90%) in LD and 10 patients (53%) in ED. The median duration of survival was 17 months in complete responders with LD and that was 12 months in those with ED. Dose limiting toxicity of the VEC regimen was leukopenia which occurred in most patients and thrombocytopenia was less frequent. Non-hematologic toxicities containing alopecia, numbness, nausea and others were acceptable and well tolerated.

Adult↗
PubMed1984

[A randomized trial of adriamycin, cyclophosphamide, ftorafur (ACF) and adriamycin, cyclophosphamide, ftorafur, methotrexate (ACFM) in patients with advanced breast cancer].

A prospective randomized trial was conducted to compare the clinical responses of sixty patients with advanced breast cancer to a combination of adriamycin, cyclophosphamide and oral ftorafur (ACF), or to a combination of ACF plus methotrexate (ACFM). The response rate was 12/28 (43%) for ACF compared with 18/30 (60%) for ACFM. Responses were seen more frequently in the cases which had less than 2 organs involved and responses of dominant metastatic sites were equal for the two arms. The duration of response for ACF was 21+ (3.5-49.5+) months as compared to 6.9 (1.9-30.8) months for ACFM (p less than 0.05). The median survival time from the start of chemotherapy for ACF was 20.8+ months, while that for ACFM was 13+ months. The major non-hematological toxicities were hair loss and GI symptoms. Hematological toxicity was similar in the two arms and manageable. No serious cardiac, renal and liver damage was seen in either arm. The response rate for ACFM was higher than that in ACF, but the addition of methotrexate to the ACF regimen did not increase complete response and prolong response duration.

Adult↗
PubMed1984

[A phase II clinical trial of oral VP 16-213 in advanced non-Hodgkin's lymphoma].

A phase II clinical trial of oral VP 16-213, a semisynthetic podophyllotoxin, was undertaken in twenty nine patients with advanced non-Hodgkin's lymphoma. All patients had received extensive prior chemotherapies including adriamycin, cyclophosphamide, vinka alkaloids and/or bleomycin and has become refractory to these drugs. The dosage of VP 16-213 was 200 mg/day p.o. bid for 5 days at 3 to 4-week intervals. There were 3 CRs (10.3%) and 6 PRs (20.7%) with a median duration of remission of 16 weeks ranging from 7 to 185+ weeks. Leukopenia less than 4 X 10(3)/cm3 and thrombocytopenia less than 100 X 10(3)/cm3 were seen in 80% and 26.7% of cases, respectively. Alopecia (100%), anorexia (44%) and nausea (26%) were observed but these were well tolerated. We conclude that the oral administration of VP 16-213 has considerable antitumor activity with no cross-resistance to vinka alkaloids, anthracyclines and alkylating agents.

Administration, Oral↗
PubMed1984

[Phase II study of mitoxantrone].

A phase II clinical trial of an anthraquinone, mitoxantrone was performed in a total of 31 patients with various advanced solid tumors and 2 patients with malignant lymphomas refractory to extensive prior chemotherapies. Mitoxantrone was administered at dosages of 2 to 4 mg/m2 with a 5-day schedule or 6 to 12 mg/m2 with a one day schedule, repeating at 4-week intervals. Of 18 evaluable patients with breast cancer, one out of 2 patients who had not been exposed to regimens containing adriamycin achieved partial response lasting 3.6 months, while the remaining 16 patients exposed to adriamycin did not respond. Leukopenia less than 4 X 10(3)/cm3 and thrombocytopenia less than 100 X 10(3)/cm3 were observed in 100% and 55% of cases, respectively. Nausea and vomiting were observed in 36% of cases. Diarrhea, pyrexia, liver damage, mucositis and palpitation were observed in one case each. No ECG abnormality was recorded.

Adult↗
PubMed1984

[A phase I trial of 4'-epiadriamycin].

A phase I study of a new anthracycline, 4'-epiadriamycin was conducted in a total of 28 patients with various advanced cancers refractory to standard chemotherapies and 26 were evaluable. A dose limiting factor was leukopenia reaching a nadir approximately 2 weeks later and about one week needed for the recovery. Thrombocytopenia was milder and less frequent than leukopenia but dose-related. Nausea and alopecia were observed in the majority of patients but vomiting was relatively rare and therefore non-hematologic toxicities were judged to be milder than adriamycin. A recommended dose for patients having prior extensive chemotherapies was determined to be 60 mg/m2 in 3 weeks intervals.

Adult↗
PubMed1984

Quantification of segmental wall motion by length-based Fourier analysis.

A new method for evaluating segmental wall motion by length-based Fourier analysis is described. Fourier analysis is performed on a series of lengths from a center to edges of the ventricle, generating parameters of percent length shortening (%LS) and phase of the segment (length-based phase). The reproducibility of the result was good, since the algorithm was automatic except for the setting of the ventricular region as a mask image to exclude surrounding blood pools. This program can be applied for quantification of ventricular wall-motion abnormalities in gated blood-pool studies, and for analysis of the timing of ventricular contraction in gated blood-pool emission computed tomography to detect the site of an accessory conduction pathway in patients with Wolff-Parkinson-White syndrome.

Arrhythmias, Cardiac↗
PubMed1984

Phase analysis in the Wolff-Parkinson-White syndrome with surgically proven accessory conduction pathways: concise communication.

Twenty-one patients with the Wolff-Parkinson-White (WPW) syndrome who underwent surgical division of the accessory conduction pathway (ACP) were studied by gated blood-pool scintigraphy. In each case, a functional image of the phase was generated, based on the fundamental frequency of the Fourier transform. The location of the ACP was confirmed by electrophysiologic study, epicardial mapping, and surgery. Phase analysis identified the side of preexcitation correctly in 16 out of 20 patients with WPW syndrome with a delta wave. All patients with right-cardiac type (N = 9) had initial contraction in the right ventricle (RV). In patients with left-cardiac type (N = 10), six had initial movement in the left ventricle (LV); but in the other four the ACPs in the anterior or lateral wall of the left ventricle (LV) could not be detected. In patients with multiple ACPs (N = 2), one right-cardiac type had initial contraction in the RV, while in the other (with an intermittent WPW syndrome) the ACP was not detected. These observations indicate that abnormal wall motion is associated with the conduction anomalies of the WPW syndrome. We conclude that phase analysis can correctly identify the side of initial contraction in the WPW syndrome before and after surgery. However, as a method of pre-operative study, it seems difficult to determine the precise site of the ACP by phase analysis alone.

Adolescent↗